George R Blumenschein

h-index

Research activity per year

Fingerprint

Dive into the research topics where George R Blumenschein is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

146 Article
11 Review article
4 Comment/debate
1 Letter

Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion
Piha-Paul, S. A., Tseng, C., Thompson, E., Stafford, R. J., Le, H., Kang, L., Fu, S., Tsimberidou, A., Blumenschein, G., Ahnert, J. R., Slopis, J. M., Hong, D., Naing, A., Meric-Bernstam, F., Ng, C. S., Westin, S. & Sood, A. K., Mar 1 2026, In: Oncologist. 31, 3, oyaf413.
Research output: Contribution to journal › Article › peer-review

Open Access
A Multicenter Open-Label Randomized Phase II Study of Osimertinib with and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)
Le, X., Patel, J. D., Shum, E., Baik, C., Sanborn, R. E., Shu, C. A., Kim, C., Fidler, M. J., Hall, R., Elamin, Y. Y., Tu, J., Blumenschein, G., Zhang, J., Gibbons, D., Gay, C., Mohindra, N. A., Chae, Y., Boumber, Y., Sabari, J. & Santana-Davila, R. & 10 others, Rogosin, S., Herzberg, B., Creelan, B., Pellini, B., Tanvetyanon, T., Heeke, S., Hernandez, M., Gray, J. E., Saltos, A. & Heymach, J. V., Feb 1 2025, In: Journal of Clinical Oncology. 43, 4, p. 403-411 9 p.
Research output: Contribution to journal › Article › peer-review

Open Access
46 Link opens in a new tab Scopus citations
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC
Ahn, M. J., Lisberg, A., Goto, Y., Sands, J., Hong, M. H., Paz-Ares, L., Pons-Tostivint, E., Pérol, M., Felip, E., Sugawara, S., Hayashi, H., Cho, B. C., Blumenschein, G., Shum, E., Lee, J. S., Heist, R. S., Cornelissen, R., Chang, W. C., Kowalski, D. & Zebger-Gong, H. & 6 others, Chargualaf, M., Gu, W., Lan, L., Howarth, P., Joseph, R. & Okamoto, I., Nov 2025, In: Journal of Thoracic Oncology. 20, 11, p. 1669-1682 14 p.
Research output: Contribution to journal › Article › peer-review

Open Access
32 Link opens in a new tab Scopus citations
Correction to: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors (Nature, (2024), 635, 8038, (462-471), 10.1038/s41586-024-07943-7)
Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Cobo, A. G., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., Juan, J. M., Min, C., Yu, Y., Pan, X., Arbour, K. C., Vokes, N., Schmidt, S. T., Molkentine, D., Owen, D. H. & Memmott, R. & 111 others, Patil, P. D., Marmarelis, M. E., Awad, M. M., Murray, J. C., Hellyer, J. A., Gainor, J. F., Dimou, A., Bestvina, C. M., Shu, C. A., Riess, J. W., Blakely, C. M., Pecot, C. V., Mezquita, L., Tabbó, F., Scheffler, M., Digumarthy, S., Mooradian, M. J., Sacher, A. G., Lau, S. C. M., Saltos, A. N., Rotow, J., Johnson, R. P., Liu, C., Stewart, T., Goldberg, S. B., Killam, J., Walther, Z., Schalper, K., Davies, K. D., Woodcock, M. G., Anagnostou, V., Marrone, K. A., Forde, P. M., Ricciuti, B., Venkatraman, D., Van Allen, E. M., Cummings, A. L., Goldman, J. W., Shaish, H., Kier, M., Katz, S., Aggarwal, C., Ni, Y., Azok, J. T., Segal, J., Ritterhouse, L., Neal, J. W., Lacroix, L., Elamin, Y. Y., Negrao, M. V., Le, X., Lam, V. K., Lewis, W. E., Kemp, H. N., Carter, B., Roth, J. A., Swisher, S., Lee, R., Zhou, T., Poteete, A., Kong, Y., Takehara, T., Paula, A. G., Parra Cuentas, E. R., Behrens, C., Wistuba, I. I., Zhang, J., Blumenschein, G. R., Gay, C., Byers, L. A., Gibbons, D. L., Tsao, A., Lee, J. J., Bivona, T. G., Camidge, D. R., Gray, J. E., Leighl, N. B., Levy, B., Brahmer, J. R., Garassino, M. C., Gandara, D. R., Garon, E. B., Rizvi, N. A., Scagliotti, G. V., Wolf, J., Planchard, D., Besse, B., Herbst, R. S., Wakelee, H. A., Pennell, N. A., Shaw, A. T., Jänne, P. A., Carbone, D. P., Hellmann, M. D., Rudin, C. M., Albacker, L., Mann, H., Zhu, Z., Lai, Z., Stewart, R., Peters, S., Johnson, M. L., Wong, K. K., Huang, A., Winslow, M. M., Rosen, M. J., Winters, I. P., Papadimitrakopoulou, V. A., Cascone, T., Jewsbury, P. & Heymach, J. V., Mar 13 2025, In: Nature. 639, 8054, p. E19
Research output: Contribution to journal › Comment/debate › peer-review

Open Access
1 Link opens in a new tab Scopus citations
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
Sands, J., Ahn, M. J., Lisberg, A., Cho, B. C., Blumenschein, G., Shum, E., Tostivint, E. P., Goto, Y., Yoh, K., Heist, R., Shimizu, J., Lee, J. S., Baas, P., Planchard, D., Pérol, M., Felip, E., Su, W. C., Zebger-Gong, H., Lan, L. & Liu, C. & 3 others, Howarth, P., Chiaverelli, R. & Paz-Ares, L., Apr 2025, In: Journal of Clinical Oncology. 43, 10, p. 1254-1265 12 p.
Research output: Contribution to journal › Article › peer-review

Open Access
89 Link opens in a new tab Scopus citations

George R Blumenschein

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion

A Multicenter Open-Label Randomized Phase II Study of Osimertinib with and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)

A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Correction to: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors (Nature, (2024), 635, 8038, (462-471), 10.1038/s41586-024-07943-7)

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

George R Blumenschein

Fingerprint

Collaborations and top research areas from the last five years

Research output

Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion

A Multicenter Open-Label Randomized Phase II Study of Osimertinib with and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)

A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Correction to: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors (Nature, (2024), 635, 8038, (462-471), 10.1038/s41586-024-07943-7)

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study